Exchange: NASDAQ·Updated 07:51 PM EST
PALI logo

PALI Palisade Bio Inc

$0.8399
$0.0855
(9.24%)
Today
Closed $0.8399
$0.0301
(3.58%)
After Hours
Mkt Cap$150.58M
Vol3.2M

About PALI

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD). Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).
57

Bullish Sentiment

How do you feel about PALI?

TwongStocks
$PALI Open market purchase reported by Director Robert Baltera Jr. https://www.sec.gov/Archives/edgar/data/1357459/000149315226053267/xslF345X06/ownership.xml Purchase 50,000 shares on Nov 17, at an avg price of $1.0057. The shares were purchased in multiple transactions at prices ranging from $0.9946 to $1.02. After the purchases, he now owns 511,904 shares of PALI.
2
ahspy853
$PALI what’s the catalyst for having target px 12-25? See three analysts with that target on Bloomberg
2
Jellysquid1
$PALI Mitch Jones… You Got Money, How about showing some Conviction in your own Company! and BUY Some Shares!!!

Advertisement|Remove ads.